4,006 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Acquired by US Bancorp DE

US Bancorp DE acquired a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,006 shares of the company’s stock, valued at approximately $40,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Kodiak Sciences by 61.4% during the fourth quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock worth $206,000 after buying an additional 7,871 shares in the last quarter. Barclays PLC grew its position in shares of Kodiak Sciences by 65.5% during the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after buying an additional 31,527 shares in the last quarter. FMR LLC lifted its stake in Kodiak Sciences by 26.4% during the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Kodiak Sciences by 5.3% during the fourth quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company’s stock worth $976,000 after purchasing an additional 4,927 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, December 9th.

Kodiak Sciences Stock Performance

KOD stock opened at $3.24 on Wednesday. Kodiak Sciences Inc. has a 1 year low of $2.19 and a 1 year high of $11.60. The firm has a market cap of $170.50 million, a P/E ratio of -0.89 and a beta of 2.26. The stock has a 50-day simple moving average of $5.66 and a 200-day simple moving average of $5.40.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.